BioCryst to Acquire Astria Therapeutics in $700M Deal to Boost Rare Disease Portfolio
BioCryst Pharmaceuticals announces $700M acquisition of Astria Therapeutics, adding promising hereditary angioedema drug to expand rare disease treatment options.
/ 932 items
#Healthcare↓
Johnson & Johnson Spins Off DePuy Synthes Amid Pricing Pressure and Strategic Focus on High-Growth Markets
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.
FDA Facility Issue May Delay Regeneron's EYLEA HD Launch
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.
Tvardi's STAT3 Drug Misses Goals in Lung Disease Trial
Tvardi's TTI-101 lung drug trial failed. High GI side effects caused dropouts, and the drug showed no lung function benefit over placebo.
Citi Raises Arcus Biosciences Price Target to $54 on Promising Cancer Drug Data
Citi upgrades Arcus Biosciences price target to $54 following impressive Phase 2 cancer treatment results showing 26.7 months median survival in gastric cancer patients.
FDA Grants Breakthrough Status to Promising Head and Neck Cancer Treatment
Bicara Therapeutics' ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits.